Lecanemab drug
About Lecanemab drug
Lecanemab, marketed as Leqembi, is a monoclonal antibody drug approved for treating early Alzheimer's disease
Key points
- Lecanemab is a monoclonal antibody for early Alzheimer's disease treatment.
- It targets and reduces amyloid beta plaques in the brain.
- Approved for mild cognitive impairment and mild dementia due to Alzheimer's.
- Slows cognitive decline by about 27% over 18 months in clinical trials.
- Administered via intravenous infusion every two weeks at a dose of 10 mg/kg. .
- Most common side effects: headache, infusion reactions, and amyloid-related imaging abnormalities.
- Not a cure, but slows progression and helps maintain daily functioning longer.
- Approved by FDA in 2023 and other regulators like Australia's TGA in 2025.
- Costly and needs monitoring for side effects during treatment.
It is indicated only for those with early Alzheimer's confirmed by amyloid beta pathology and has not been studied for moderate or severe Alzheimer's disease stages.
Download Pdf
